Baseline Evaluation of the AIM Higher Initiative: Establishing the Mark From Which to Measure

Gina D. Johnson

Kelly Moore

Barry Fortner

toxins, chemotherapy, Assessment, management
ONF 2007, 34(3), 729-734. DOI: 10.1188/07.ONF.729-734

Purpose/Objectives: To collect baseline measurements before the implementation of interventions associated with the AIM (Assessment Information Management) Higher Initiative—a quality improvement program intended to improve symptom assessment, management, and information distribution for five chemotherapy-related symptom groups: anemia, neutropenia, diarrhea and constipation, nausea and vomiting, and depression and anxiety.

Design: Subject telephone interviews and chart reviews.

Setting: 15 community oncology clinics in the United States.

Sample: 376 adult patients with cancer who visited a healthcare provider before the start of a chemotherapy cycle; patients were enrolled in the study after the initiation of chemotherapy, with at least one chemotherapy cycle remaining.

Methods: Subject interviews and chart reviews to determine the frequency, assessment, and management of and information about target symptoms.

Main Research Variables: The frequency of target chemotherapyrelated symptoms and occurrence of symptom-specific assessment, information provided, and management.

Findings: The five target symptoms had occurred in a considerable proportion of patients with cancer receiving chemotherapy during their most recent chemotherapy cycles. At a substantial number of clinic visits, no documentation of cancer-related symptom assessment, information distribution, or management occurred.

Conclusions: Chemotherapy-related symptoms occur frequently but often are not assessed, managed, or handled with appropriate patient information.

Implications for Nursing: Findings in the baseline evaluation illustrate the need to improve supportive care—a key responsibility of oncology nurses.

Jump to a section


    Bonadonna, G., Moliterni, A., Zambetti, M., Daidone, M.G., Pilotti, S., Gianni, L., et al. (2005). 30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ, 330, 217.
    Cappozzo, C. (2004). Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia. Oncology Nursing Forum, 31, 569-576.
    Cella, D. (1998). Factors influencing quality of life in cancer patients: Anemia and fatigue. Seminars in Oncology, 25(3, Suppl. 7), 43-46.
    Cella, D., Zagari, M.J., Vandoros, C., Gagnon, D.D., Hurtz, H.J., & Nortier, J.W. (2003). Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. Journal of Clinical Oncology, 21, 366-373.
    Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11, 570-579.
    Chang, V.T., Thaler, H.T., Polyak, T.A., Kornblith, A.B., Lepore, J.M., & Portenoy, R.K. (1998). Quality of life and survival: The role of multidimensional symptom assessment. Cancer, 83, 173-179.
    Chelf, J.H., Agre, P., Axelrod, A., Cheney, L., Cole, D.D., Conrad, K., et al. (2001). Cancer-related patient education: An overview of the last decade of evaluation and research. Oncology Nursing Forum, 28, 1139-1147.
    Cope, D.G. (2001). Management of chemotherapy-induced diarrhea and constipation. Nursing Clinics of North America, 36, 695-707.
    Crawford, J., Cella, D., Cleeland, C.S., Cremieux, P.Y., Demetri, G.D., Sarokhan, B.J., et al. (2002). Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 95, 888-895.
    Crawford, J., Dale, D.C., & Lyman, G.H. (2004). Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer, 100, 228-237.
    Dodd, M., Janson, S., Facione, N., Faucett, J., Froelischer, E.S., Humphreys, J., et al. (2001). Advancing the science of symptom management. Journal of Advanced Nursing, 33, 668-676.
    Donohue, R.B., & Carbo, G. (2004, April). Development of a neutropenia risk assessment tool. Presented at the Oncology Nursing Society 29th Annual Congress, Anaheim, CA.
    Fernsler, J.I., & Cannon, C.A. (1991). The whys of patient education. Seminars in Oncology Nursing, 7, 79-86.
    Fortner, B., Okon, T., Schwartzberg, L., Tauer, K., & Houts, A.C. (2003). The Cancer Care Monitor: Psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. Journal of Pain and Symptom Management, 26, 1077-1092.
    Fortner, B., Tauer, K., Zhu, L., Ma, L., & Schwartzberg, L. (2004). The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver: A national survey. Community Oncology, 1, 211-217.
    Fortner, B.V., Okon, T.A., Ashley, J., Kepler, G., Chavez, J., Tauer, K., et al. (2003). The Zero Acceptance of Pain (ZAP) quality improvement project: Evaluation of pain severity, pain interference, global quality of life, and pain-related costs. Journal of Pain and Symptom Management, 25, 334-343.
    Gillespie, T.W. (2002). Effects of cancer-related anemia on clinical and quality-of-life outcomes. Clinical Journal of Oncology Nursing, 6, 206-211.
    Gillespie, T.W. (2003). Anemia in cancer: Therapeutic implications and interventions. Cancer Nursing, 26, 119-128.
    Kash, K.M., Mago, R., & Kunkel, E.J. (2005). Psychosocial oncology: Supportive care for the cancer patient. Seminars in Oncology, 32, 211-218.
    Kuderer, N.M., Crawford, J., Dale, D.C., & Lyman, G.H. (2005). Metaanalysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy [Abstract 8117]. Journal of Clinical Oncology, 23(16, Pt. 1), 758s.
    Kwak, L.W., Halpern, J., Olshen, R.A., & Horning, S.J. (1990). Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. Journal of Clinical Oncology, 8, 963-977.
    Larson, P.J., Uchinuno, A., Izumi, S., Kawano, A., Takemoto, A., Shigeno, M., et al. (1999). An integrated approach to symptom management. Nursing and Health Sciences, 1, 203-210.
    Lyman, G.H., Crawford, J., Wolff, D.A., Culakova, E., Poniewierski, M.S., & Dale, D.C. (2005, May). A risk model for first cycle febrile neutropenia in cancer patients receiving systemic chemotherapy. Poster presented at the Annual Meeting of the American Society of Clinical Oncology, Orlando, FL.
    Lyman, G.H., Dale, D.C., & Crawford, J. (2003). Incidence and predictors of low dose intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. Journal of Clinical Oncology, 21, 4524-4531.
    Lyman, G.H., & Kuderer, N.M. (2003). Cost effectiveness of myeloid growth factors in cancer chemotherapy. Current Hematology Reports, 2, 471-479.
    National Comprehensive Cancer Network. (2007). NCCN clinical practice guidelines in oncology™: Antiemesis-v.1.2007. Retrieved April 20, 2007, from
    National Institutes of Health. (2002, July). State-of-the-science conference statement. Symptom management in cancer: Pain, depression, and fatigue. Retrieved October 1, 2002, from
    Ropka, M.E., Padilla, G., & Gillespie, T.W. (2005). Risk modeling: Applying evidence-based risk assessment in oncology nursing practice. Oncology Nursing Forum, 32, 49-56.
    Ropka, M.E., & Spencer-Cisek, P. (2001). PRISM: Priority Symptom Management project phase I: Assessment. Oncology Nursing Forum, 28, 1585-1594.
    Rutledge, D.N., & McGuire, C. (2004). Evidence-based symptom management. In C.H. Yarbro, M.H. Frogge, & M. Goodman (Eds.), Cancer symptom management (pp. 3-14). Sudbury, MA: Jones and Bartlett.
    Sarna, L. (1998). Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. Oncology Nursing Forum, 25, 1041-1048.
    Thomas, R., Daly, M., Perryman, B., & Stockton, D. (2000). Forewarned is forearmed—Benefits of preparatory information on video cassette for patients receiving chemotherapy or radiotherapy—A randomized controlled trial. European Journal of Cancer, 36, 1536-1543.
    Tsavaris, N., Kosmas, C., Mylonakis, N., Bacoyiannis, C., Kalergis, G., Vadiaka, M., et al. (2000). Parameters that influence the outcome of nausea and emesis in cisplatin-based chemotherapy. Anticancer Research, 20, 4777-4783.
    Ward, S.E., Goldberg, N., Miller-McCauley, V., Meuller, C., Nolan, A., Pawlik-Plank, D., et al. (1993). Patient-related barriers to management of cancer pain. Pain, 52, 319-324.
    White, N., Maxwell, C., Michelson, J., & Bedell, C. (2005). Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices. Cancer Nursing, 28, 62-69.